Last reviewed 2026-05-24 · How we verify

Gumbix (aminomethylbenzoic acid)

Gumbix (generic name: aminomethylbenzoic acid) is a aminomethylbenzoic acid drug. It is currently in unknown development.

Gumbix works by interacting with a specific molecular target to produce a therapeutic effect.

Gumbix is an antifibrinolytic agent. Its exact mechanism of action is currently unknown.

At a glance

Mechanism of action

Imagine your body's cells have locks on them, and Gumbix is a key that fits into one of those locks. When it binds to the lock, it triggers a series of events that help to treat a particular disease or condition. This is a simplified explanation of how Gumbix works at a molecular level.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Efficacy and Safety Trial of Using Ultra-Pulsed Shockwaves to Deliver Tranexamic Acid for the Treatment of Melasma (NA)
• Glue Application in the Treatment of Low-Output Fistulas (NA)
• Glue Sealing for Patients With Low-Output ECFs (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Gumbix CI brief — competitive landscape report
• Gumbix updates RSS · CI watch RSS
• portfolio CI

Frequently asked questions about Gumbix

Related

• Drug class: All aminomethylbenzoic acid drugs
• Manufacturer: — full pipeline
• Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing